<?xml version='1.0' encoding='utf-8'?>
<document id="8570437"><sentence text="The emerging role of valproate in bipolar disorder and other psychiatric disorders."><entity charOffset="21-30" id="DDI-PubMed.8570437.s1.e0" text="valproate" /></sentence><sentence text="Although valproate, a simple branched-chain fatty acid, is generally considered to be an antiepileptic agent, a large literature dating back to 1966 describes its use in primary psychiatric disorders"><entity charOffset="9-18" id="DDI-PubMed.8570437.s2.e0" text="valproate" /><entity charOffset="44-54" id="DDI-PubMed.8570437.s2.e1" text="fatty acid" /><pair ddi="false" e1="DDI-PubMed.8570437.s2.e0" e2="DDI-PubMed.8570437.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8570437.s2.e0" e2="DDI-PubMed.8570437.s2.e1" /></sentence><sentence text=" The significant role that gamma-aminobutyric acid plays in mood provided the rationale to examine valproate in this regard"><entity charOffset="27-50" id="DDI-PubMed.8570437.s3.e0" text="gamma-aminobutyric acid" /><entity charOffset="91-108" id="DDI-PubMed.8570437.s3.e1" text="examine valproate" /><pair ddi="false" e1="DDI-PubMed.8570437.s3.e0" e2="DDI-PubMed.8570437.s3.e0" /><pair ddi="false" e1="DDI-PubMed.8570437.s3.e0" e2="DDI-PubMed.8570437.s3.e1" /></sentence><sentence text=" Numerous uncontrolled as well as placebo- and lithium-controlled studies verified the drug's efficacy in the short-term management of bipolar and schizoaffective disorders"><entity charOffset="47-54" id="DDI-PubMed.8570437.s4.e0" text="lithium" /></sentence><sentence text=" The response appears to be independent of response to traditional therapies such as lithium, neuroleptics, and carbamazepine, and may be maintained for extended periods of time"><entity charOffset="85-92" id="DDI-PubMed.8570437.s5.e0" text="lithium" /><entity charOffset="112-125" id="DDI-PubMed.8570437.s5.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.8570437.s5.e0" e2="DDI-PubMed.8570437.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8570437.s5.e0" e2="DDI-PubMed.8570437.s5.e1" /></sentence><sentence text=" Valproate should be considered not only in patients with mood disorders who are intolerant of or nonresponsive to traditional therapies, but also in those with rapid cycling, electroencephalographic abnormalities, head trauma antedating the onset of psychiatric illness, or any other factor suggesting an organic component"><entity charOffset="1-10" id="DDI-PubMed.8570437.s6.e0" text="Valproate" /></sentence><sentence text=" Preliminary uncontrolled studies suggest that the drug may also eventually play a role in the management of panic disorder and behavioral dyscontrol (agitation, aggression, temper outbursts)" /><sentence text=" Its adverse event profile is well known from years of experience in the management of epilepsy and does not appear to be altered in the presence of psychiatric disorders" /><sentence text=" Similarly, the drug-drug interaction potential of valproate is reasonably well known, although further research into interactions with psychotropic agents is warranted"><entity charOffset="51-60" id="DDI-PubMed.8570437.s9.e0" text="valproate" /></sentence><sentence text="" /></document>